These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 17692126)

  • 1. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
    Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
    Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
    Hadji P; Ziller M; Kieback DG; Menschik T; Kalder M; Kuck J; Hasenburg A
    Breast; 2009 Jun; 18(3):159-64. PubMed ID: 19364653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
    Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
    Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
    Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
    Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
    McCloskey EV; Hannon RA; Lakner G; Fraser WD; Clack G; Miyamoto A; Finkelman RD; Eastell R
    Eur J Cancer; 2007 Nov; 43(17):2523-31. PubMed ID: 18029171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
    Lønning PE; Geisler J; Krag LE; Erikstein B; Bremnes Y; Hagen AI; Schlichting E; Lien EA; Ofjord ES; Paolini J; Polli A; Massimini G
    J Clin Oncol; 2005 Aug; 23(22):5126-37. PubMed ID: 15983390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
    Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
    Gnant M; Baselga J; Rugo HS; Noguchi S; Burris HA; Piccart M; Hortobagyi GN; Eakle J; Mukai H; Iwata H; Geberth M; Hart LL; Hadji P; El-Hashimy M; Rao S; Taran T; Sahmoud T; Lebwohl D; Campone M; Pritchard KI
    J Natl Cancer Inst; 2013 May; 105(9):654-63. PubMed ID: 23425564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
    Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
    Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
    Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
    Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
    Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.